WO2002051410A3 - Phenylthiazole and thiazoline derivatives and their use as antiparasitics - Google Patents

Phenylthiazole and thiazoline derivatives and their use as antiparasitics Download PDF

Info

Publication number
WO2002051410A3
WO2002051410A3 PCT/EP2001/015119 EP0115119W WO02051410A3 WO 2002051410 A3 WO2002051410 A3 WO 2002051410A3 EP 0115119 W EP0115119 W EP 0115119W WO 02051410 A3 WO02051410 A3 WO 02051410A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
formula
heteroaryl
aryl
heterocycloalkyl
Prior art date
Application number
PCT/EP2001/015119
Other languages
French (fr)
Other versions
WO2002051410A2 (en
Inventor
Joerg Fruechtel
Sandra Koch
Trevor Newton
Christian Miculka
Darryl Mcconnell
Joachim Hofmann
Original Assignee
Akzo Nobel Nv
Joerg Fruechtel
Sandra Koch
Trevor Newton
Christian Miculka
Darryl Mcconnell
Joachim Hofmann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv, Joerg Fruechtel, Sandra Koch, Trevor Newton, Christian Miculka, Darryl Mcconnell, Joachim Hofmann filed Critical Akzo Nobel Nv
Publication of WO2002051410A2 publication Critical patent/WO2002051410A2/en
Publication of WO2002051410A3 publication Critical patent/WO2002051410A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a new class of antiparatisitcs. The compounds found with the present invention are substituted thiazole- and thiazoline derivatives. The present invention is based on the discovery that such compounds have been found to have antiparasitic activity. The present invention relates to 4-phenyl thiazole derivatives of the following general formula (I): X in formula (I) may be N-R6 or a bond. R1 in formula (I) may be (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl, (3-13C)heteroaryl, (6-14C)aryl(1-8C)alkyl or (3-13C)heteroaryl(1-8C)alkyl. R2 in formula (I) may be SO¿2?NR?7R8, CONR7R8 or NR7R8 R3 and R4¿ in formula (I) may independently be selected from H, halogen, (1-8C)alkyl, hydroxy, (1-8) alkoxy, cyano, nitro, (1-8C) alkoxycarbonyl, (1-8C)(di)alkylamino and (6-14C)(di)arylamino, or R?3 and R4¿ are joined together in a 5-7 membered carbocyclic or heterocyclic ring. R5 in formula (I) may be a halogen atom, (1-8C)alky, hydroxy, (1-8C)alkoxy, cyano, nitro, (1-8C)alkoxycarbonyl, (1-8C)(di)alkylamino or (6-14C)(di)arylamino. 'n' may be 0-3. R6 in formula (I) may be H or (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl, (3-13C)heteroaryl, (6-14C)aryl(1-8C)alkyl or (3-13C)heteroaryl(1-8C)alkyl. R?7 and R8¿ in formula (I) may independently be selected from H, (1-8C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (3-8C)cycloalkyl, (2-7C)heterocycloalkyl, (6-14C)aryl, (3-13C)heteroaryl, (6-14C)aryl(1-8C)alkyl and (3-13C)heteroaryl(1-8C)alkyl, or R?7 and R8¿ are joined together in a (2-7C) heterocycloalkyl ring.
PCT/EP2001/015119 2000-12-22 2001-12-19 Phenylthiazole and thiazoline derivatives and their use as antiparasitics WO2002051410A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00204739 2000-12-22
EP00204739.7 2000-12-22

Publications (2)

Publication Number Publication Date
WO2002051410A2 WO2002051410A2 (en) 2002-07-04
WO2002051410A3 true WO2002051410A3 (en) 2003-07-31

Family

ID=8172519

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/015119 WO2002051410A2 (en) 2000-12-22 2001-12-19 Phenylthiazole and thiazoline derivatives and their use as antiparasitics

Country Status (1)

Country Link
WO (1) WO2002051410A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080019213A (en) 2005-05-09 2008-03-03 아칠리온 파르마세우티칼스 인코포레이티드 Thiazole compounds and methods of use
EP2164846A2 (en) 2007-05-22 2010-03-24 Achillion Pharmaceuticals, Inc. Heteroaryl substituted thiazoles and their use as antiviral agents.
CN102579606B (en) * 2011-01-18 2015-03-11 瑞普（天津）生物药业有限公司 Anticoccidial traditional Chinese medicine preparation and preparation method thereof
EA037918B1 (en) 2011-12-21 2021-06-07 Новира Терапьютикс, Инк. Hepatitis b antiviral agents
UA123256C2 (en) 2012-08-28 2021-03-10 ЯНССЕН САЙЄНСІЗ АЙРЛЕНД ЮСі Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
HUE034820T2 (en) 2013-02-28 2018-02-28 Janssen Sciences Ireland Uc Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
ES2640063T3 (en) 2013-04-03 2017-10-31 Janssen Sciences Ireland Uc N-phenyl-carboxamide derivatives and their use as medicines for the treatment of hepatitis B
JO3603B1 (en) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6348978B2 (en) 2013-07-25 2018-06-27 ヤンセン・サイエンシズ・アイルランド・ユーシー Glyoxamide-substituted pyrrolamide derivatives and their use as pharmaceuticals for treating hepatitis B
ES2655518T3 (en) 2013-10-23 2018-02-20 Janssen Sciences Ireland Uc Carboxamide derivatives and their use as medicines for the treatment of hepatitis B
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
KR20160128305A (en) 2014-02-05 2016-11-07 노비라 테라퓨틱스, 인코포레이티드 Combination therapy for treatment of hbv infections
CN110483484A (en) 2014-02-06 2019-11-22 爱尔兰詹森科学公司 Sulfamoyl pyrrole amides derivative and its purposes for being used to treat hepatitis B as drug
US10071976B2 (en) * 2014-03-07 2018-09-11 Sanford Burnham Prebys Medical Discovery Institute Small molecule fatty acid synthase inhibitors
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
US9884831B2 (en) 2015-03-19 2018-02-06 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
EP3356328A1 (en) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Crystalline forms of a hepatitis b antiviral agent
KR20180129943A (en) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 Formulations and methods involving capsid assembly inhibitors
EP3502109A1 (en) * 2017-12-20 2019-06-26 Consejo Superior De Investigaciones Científicas Triazole-phenyl-thiazole heterocycles as innovative inhibitors of trypanothione reductase and their use as leishmanicides
CA3090125A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN113454077A (en) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 Amide derivatives for the treatment of HBV infection or HBV-induced diseases
BR112021021454A2 (en) 2019-05-06 2021-12-21 Janssen Sciences Ireland Unlimited Co Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3676450A (en) * 1969-10-30 1972-07-11 Ciba Geigy Corp -4-(isothi ocyanophenyl)-thiazoles
JPS58124758A (en) * 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd Benzenesulfonamide derivative
EP0237695A2 (en) * 1986-01-17 1987-09-23 MERCK PATENT GmbH 1,4-Dihydropyridines

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3676450A (en) * 1969-10-30 1972-07-11 Ciba Geigy Corp -4-(isothi ocyanophenyl)-thiazoles
JPS58124758A (en) * 1982-01-20 1983-07-25 Fujisawa Pharmaceut Co Ltd Benzenesulfonamide derivative
EP0237695A2 (en) * 1986-01-17 1987-09-23 MERCK PATENT GmbH 1,4-Dihydropyridines

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CHAUHAN, P. M. S. ET AL: "Synthesis and antiparasitic activity of 4-(aryl/heteroarylamino)-7- chloroquinolines", INDIAN J. CHEM., SECT. B (1985), 24B(11), 1154-7, XP001031846 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FUJISAWA PHARMACEUTICAL CO., LTD., JAPAN: "Benzenesulfonamide derivatives", XP002227142, retrieved from STN Database accession no. 100:34278 HCA *
EBEID, M. Y. ET AL: "Synthesis of some new p-(cinnamoylanilino)pyrimidines and other related products of possible antischistosomal activity", EGYPT. J. PHARM. SCI. (1991), 32(1-2), 381-7, XP001031865 *
KHADSE, B. G. ET AL: "Synthesis and study of 2-[(4-aryl-2-thiazolyl)amino]pyrido[3,2-d]thiazole and 2-[p-(2-substituted-4-thiazolyl)arylamino]pyrido[3,2-d]thiazoles as possible anthelmintic agents", BULL. HAFFKINE INST. (1976), 4(2), 60-3, XP001032463 *
KHADSE, B. G. ET AL: "Synthesis and study of 2-[p-(2-substituted-4-thiazolyl)arylamino]pyrido(3 2-d)thiazoles as possible anthelmintic agents", BULL. HAFFKINE INST. (1977), 5(2), 56-9, XP001032466 *
KULKARNI, D. G. ET AL: "Synthesis and study of new 2-(substituted-thiazolyl phenylamino) pyrido (3,2-d) thiazoles as possible anthelmintic agents", INDIAN J. PHARM. SCI. (1981), 43(2), 37-9, XP001031875 *
MANIAN, ARVIND K. ET AL: "Synthesis of 2-substituted- anilino / phenyl /benzyl-5-substituted 4-(phenylamido)-(3-o-chlorophenyl-5- methylisoxazolyl) thiazoles as potential antitubercular and antimicrobial agents", INDIAN DRUGS (1994), 31(9), 442-4, XP008005370 *
PATIL, V. H. ET AL: "2-Arylamino-4-[4'-(benzenesulfonamido)phenyl] thiazoles", JOURNAL OF THE INDIAN CHEMICAL SOCIETY (1982), 59(8), 1000-1, XP008012336 *
SHINGARE, M. S. ET AL: "Synthesis of 2-(substituted phenyl sulfonamido)-4-(3'-sulfamyl-4'- substituted phenyl) thiazoles - Part II", ACTA CIENCIA INDICA, CHEMISTRY (1980), 6(1), 40-1, XP008012361 *
SHINGARE, M. S. ET AL: "Synthesis of sulfonamides derived from 2-acetamido-4-(3'-chlorosulfonyl-4 aryl)thiazoles", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY (1979), 18B(3), 277-9, XP008012360 *

Also Published As

Publication number Publication date
WO2002051410A2 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
WO2002051410A3 (en) Phenylthiazole and thiazoline derivatives and their use as antiparasitics
MXPA04000403A (en) 7-amino triazolopyrimidines for controlling harmful fungi.
EP0860428A3 (en) Sulphonamide derivatives
HUP0400467A2 (en) 2-iminopyrrolidine derivatives, pharmaceutical compositions containing them and their use
GB0113233D0 (en) Chemical compounds
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
MY119238A (en) 8-quinolinzanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
WO2006032466A3 (en) New bicyclic antibiotics
HUP0400828A2 (en) Fused heterocyclic aminopyrimidines, their use and pharmaceutical compositions containing them
AR036093A1 (en) COMPOUNDS DERIVED FROM TIAZOLIDINILO, PIRROLIDINILO, OXAZOLIDINILO, PIPERIDILO, MORFOLINILO AND TIOMORFOLINILO, ITS USE, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM, AND INTERMEDIARY COMPOUNDS
AR058406A1 (en) PROCHINETICIN RECEIVER ANTAGONISTS 1
SE0101579D0 (en) New compounds
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AR047339A1 (en) DERIVATIVES OF DIFENILAZETIDONA. OBTAINING PROCESS.
RS20060316A (en) Derivatives of n-/heteroaryl(piperidine-2-yl)methyl/ benzamide, preparation method and application of same in therapeutics
HUP0302367A2 (en) Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors and pharmaceutical compositions containing them
MX2009004920A (en) Novel aminopyrimidine derivatives as plk1 inhibitors.
ATE227719T1 (en) HETEROARYL-CYCLIC ACETALES
WO2002074726A3 (en) Aniline derivatives useful as phosphodiesterase 4 inhibitors
WO2008136444A1 (en) Fused heterocyclic derivative
TW200607808A (en) Pyrido-pyrimidine derivatives, preparation thereof and application thereof
MXPA05008584A (en) Heterocyclic compounds useful as nurr-1 activators.
RS20050458A (en) Tetrahydroquinoline derivatives
IE872773L (en) 4,5-DIHYDRO and 4,5,6,7-TETRAHYDROPYRAZOLO£1.5-a|PYRIMIDINES
UA66756C2 (en) Piperazine and piperidine derivatives

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX MZ NO NZ PH PL RO RU SG SI SK SL TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP